BCDA 8-K discloses Farhan Shahab as new VP of Quality

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) reported an organizational update. The company announced in an 8-K that, on November 24, 2025, it issued a press release appointing Farhan Shahab as Vice President of Quality. This role typically oversees and supports quality systems and compliance for products and operations, which is important for companies operating in regulated medical and life science markets.

The press release describing the appointment is included as Exhibit 99.1, and the company notes that this information is being furnished, not filed, under securities laws, meaning it is provided for disclosure purposes without triggering certain liability provisions.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0000925741 0000925741 2025-11-24 2025-11-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 24, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01         Other Events.

On November 24, 2025, BioCardia, Inc. issued a press release announcing the appointment of Farhan Shahab as Vice President of Quality.

A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.

The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		BioCardia, Inc. press release dated November 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.

Peter Altman, Ph.D.

President and Chief Executive Officer

Date: November 24, 2025

FAQ

What did BioCardia (BCDA) announce in this 8-K filing?

BioCardia announced that it issued a press release on November 24, 2025, appointing Farhan Shahab as Vice President of Quality.

What new position was disclosed for BioCardia (BCDA) on November 24, 2025?

BioCardia disclosed the appointment of Farhan Shahab as its Vice President of Quality in a press release furnished with the 8-K.

Which exhibit in the BioCardia (BCDA) 8-K contains the press release?

The press release announcing the appointment of the Vice President of Quality is included as Exhibit 99.1 to the 8-K.

Is the BioCardia (BCDA) press release considered filed or furnished?

The company states that the information in Item 8.01, including Exhibit 99.1, is being furnished and is not deemed "filed" under the Exchange Act.

Who signed the BioCardia (BCDA) 8-K reporting the management change?

The 8-K was signed on behalf of BioCardia by Peter Altman, Ph.D., the company’s President and Chief Executive Officer.